Trial Profile
Evogliptin Versus Linagliptin for the Effect on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency: a Multicenter, Randomised, Double-blind, Active-controlled, Non-inferiority Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Evogliptin (Primary) ; Linagliptin (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 19 Sep 2019 Status changed from recruiting to completed.
- 19 Sep 2018 New trial record